Particle Sciences has entered into an exclusive agreement with Actavis plc to develop an undisclosed complex generic product. Particle Sciences is responsible for design, formulation and cGMP supplies, and will receive undisclosed milestone and revenue- based payments. Actavis will be responsible for clinical testing, regulatory filings and marketing.    “We have worked with Actavis on a number of projects in the past,” said Mark Mitchnick, Particle Sciences’ chief executive of...